Metrics as of 10/17/2026, 04:26 AM (Berlin time), refresh in progress.
AN2 Therapeutics Stock
AN2 Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Eric E. Easom
- Employees
- 21
- Market cap
- $128 M
- IPO
- 25/03/2022
AN2 Therapeutics, Inc. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of treatments for uncommon, long-term, and severe infectious conditions. A key focus of their pipeline is epetraborole, an investigational oral medication designed for once-daily…
AN2 Therapeutics stock: price history
1D
-6.1%
1W
-23.2%
1M
-36.7%
6M
-6.4%
YTD
+196.5%
1Y
+186.4%
2Y
+218.9%
5Y
–
10Y
–
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~49% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 13/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about AN2 Therapeutics
Analyst assessment of AN2 Therapeutics
PRICE TARGET LOW
US$9.00
CONSENSUS
US$9.00
MEDIAN
US$9.00
PRICE TARGET HIGH
US$9.00
0
STRONG BUY
5
BUY
3
HOLD
0
SELL
0
STRONG SELL
8
TOTAL · Buy
As of: 14/05/2026
AN2 Therapeutics stock metrics
P/E
-3.16
P/B
1.99
EV/EBITDA
-2.22
RETURN ON EQUITY
-10.8%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
59.1%
FLOAT SHARES
22,287,399
AVG. DAILY VOLUME (30D)
295,471
Insider transactions (SEC)
Marks Gilbert Lynn
Martin Patricia A.
Aziz Kabeer
Trenor Cameron C. III
Readnour Robin Shane
Institutional holders
Dividends
Comparable stocks
Frequently asked questions about AN2 Therapeutics stock
What does AN2 Therapeutics do?
AN2 Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Eric E. Easom, the company employs around 21 people.
The IPO was on 25/03/2022; the stock trades on NASDAQ under the ticker ANTX.
What do analysts say about AN2 Therapeutics stock?
8 analysts rate the stock, the consensus is Buy (as of 14/05/2026).
The average price target is US$9.00, ranging from US$9.00 to US$9.00, with a median of US$9.00.
This is an external assessment, not a statement by Market Jury.
When does AN2 Therapeutics report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly 49% stronger than usual.
Does AN2 Therapeutics pay a dividend?
Yes. The last dividend was US$0.66 per share.
The dividend yield is 0.0% (as of 30/06/2026).
Which stocks are comparable to AN2 Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get AN2 Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess AN2 Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.